Clinical trials: Sodium-glucose Cotransporter-2 Inhibitor
Diabetic Ketoacidosis, Postoperative Care
Postoperative Euglycemic Ketoacidosis Frequency in Sodium-Glucose Cotransporter-2 Inhibitor Users
The goal of this observational study is to determine the frequency of postoperative euglycemic diabetic ketoacidosis (EDKA) in patients receiving Sodium- Glucose Cotransporter-2 (SGLT-2) inhibitors.
- Trial name
- SGLT-2I (NCT07127406)
- Where
- Turkey (Türkiye)
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Kocaeli City Hospital
Type 2 Diabetes Mellitus, Nonalcoholic Fatty Liver Disease
Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
This prospective, open-label, randomized clinical study will evaluate the effect of empagliflozin 10 mg daily, added to standard T2DM treatment, on liver fat and hepatic parameters in adults with type 2 diabetes and nonalcoholic…
- Trial name
- EMPA-LIVER (NCT07915596)
- Testing
- Empagliflozin 10/15 mg administered orally once daily in addition to standard treatment for type 2 diabetes mellitus.
- Where
- Bangladesh
- Volunteers
- 792 people, healthy volunteers welcome
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Diabetes Mellitus, Cellular Senescence
Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Type 2 Diabetes
Patients with type 2 diabetes (T2D) are more prevalent with aging-related comorbidities and frailty, which leads to a shorter life expectancy than non-diabetic individuals and that this excess mortality is largely attributable to…
- Conditions
- Diabetes Mellitus, Cellular Senescence, Sodium-Glucose Transporter 2 Inhibitors
- Trial name
- NCT05975528
- Testing
- SGLT2 inhibitor, Glimepiride
- Where
- South Korea
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Heart Failure, Acute Kidney Injury
Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome
The overall objective of this study is to determine whether the addition of SGLT2 inhibitors to usual care in hospitalized patients with heart failure associated acute kidney injury is safe and efficacious.
- Trial name
- NCT07273838
- Testing
- Dapagliflozin 10mg Tab
- Where
- 2 sites in United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Yale University